Home / Market News / $DXCM
benzinga Corporate Catalyst Impact 55/100 ● positive

RBC Capital Maintains Outperform on DexCom, Raises Price Target to $105

Oct 1, 2026, 1:04 PM UTC · Primary ticker $DXCM

RBC Capital analyst Kendall Au reiterated an Outperform rating on DexCom (DXCM) and increased the price target from $90 to $105. This indicates a positive outlook from the analyst, suggesting potential upside for the stock based on their valuation.

RBC Capital analyst Kendall Au maintained an 'Outperform' rating on DexCom and raised the price target from $90 to $105. This action signals continued confidence from a prominent financial institution in DexCom's future performance and valuation. For traders, this represents a positive sentiment indicator, potentially leading to short-term upward price momentum as investors react to the increased target. The long-term implication is that the analyst sees sustained growth or value in DexCom, which could attract more institutional investment. The key opportunity for traders is to capitalize on any immediate positive reaction to the news, while the risk is that the market may have already priced in such expectations or that other factors could overshadow this analyst upgrade.

$DXCM positive Analyst price target increase
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.